Beta Bionics (NASDAQ:BBNX) Upgraded at UBS Group

UBS Group upgraded shares of Beta Bionics (NASDAQ:BBNX) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Lake Street Capital raised their price target on shares of Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Bank of America cut Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. TD Cowen initiated coverage on Beta Bionics in a research report on Monday, January 26th. They set a “hold” rating and a $17.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Finally, Stifel Nicolaus reduced their target price on Beta Bionics from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average price target of $26.42.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $14.12 on Monday. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The company’s 50 day moving average price is $23.32 and its 200-day moving average price is $22.60. The stock has a market capitalization of $621.70 million and a price-to-earnings ratio of -3.23.

Insider Buying and Selling

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares in the company, valued at approximately $1,258,391.42. The trade was a 31.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of Beta Bionics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the transaction, the insider directly owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. This represents a 8.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,490 shares of company stock valued at $960,835 in the last ninety days.

Institutional Investors Weigh In On Beta Bionics

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Beta Bionics in the 2nd quarter worth $13,817,000. Sands Capital Alternatives LLC raised its stake in shares of Beta Bionics by 15.0% in the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after purchasing an additional 466,331 shares during the last quarter. Soleus Capital Management L.P. raised its stake in shares of Beta Bionics by 12.5% in the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after purchasing an additional 424,817 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Beta Bionics during the fourth quarter valued at $10,338,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.